Trevi Therapeutics, Inc. (TRVI) 10-Year Financial Performance & Capital Metrics

TRVI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Show more

Revenue $0
EBITDA -$51M -52.0%
Net Income -$48M -64.8%
EPS (Diluted) -0.47 -62.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -52.59% -71.9%
ROIC -65.46% -100.1%
Debt/Equity 0.01 -36.1%
Interest Coverage -12881.00 -14746.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 83 (top 17%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Expensive at 10.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.12%

ROCE

10Y Avg-126.56%

5Y Avg-59.84%

3Y Avg-45.11%

Latest-56.01%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	4K	0	23K	39K	47K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-4K	0	-23K	-39K	-47K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-0.7%	-0.21%	1%	-	-	-
Operating Expenses+	8.62M	8.24M	18.41M	26.64M	32.49M	32.48M	29.91M	33.92M	51.52M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.71M	2.14M	4.34M	7.31M	10.16M	9.49M	10.07M	10.24M	12.15M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	6.91M	6.09M	14.07M	19.34M	22.33M	22.98M	19.83M	23.68M	39.38M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	-24K	0	0	0	0	0	0	0
Operating Income+	-8.63M	-8.24M	-18.41M	-26.64M	-32.49M	-32.48M	-29.91M	-33.92M	-51.52M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.04%	-1.23%	-0.45%	-0.22%	0%	0.08%	-0.13%	-0.52%
EBITDA+	-8.62M	-8.23M	-18.39M	-26.61M	-32.44M	-32.43M	-29.86M	-33.8M	-51.38M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.05%	-1.23%	-0.45%	-0.22%	0%	0.08%	-0.13%	-0.52%
D&A (Non-Cash Add-back)	4K	4K	23K	39K	47K	50K	43K	123K	147K
EBIT	-8.63M	-8.24M	-20.5M	-26.64M	-32.32M	-32.76M	-28.02M	-28.71M	-47.94M
Net Interest Income+	0	-3.27M	-18K	792K	-278K	-1.19M	960K	4.36M	3.6M
Interest Income	2.61M	69K	156K	792K	178K	10K	1.74M	4.75M	3.6M
Interest Expense	0	3.34M	174K	0	456K	1.2M	780K	391K	4K
Other Income/Expense	-2.47M	-4.65M	-2.26M	577K	-287K	-1.49M	719K	4.83M	3.58M
Pretax Income+	-11.1M	-12.89M	-20.67M	-26.07M	-32.78M	-33.96M	-29.19M	-29.1M	-47.94M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	-8K	-26K	-124K	-18K	-18K	-21K	-36K	-32K	-30K
Effective Tax Rate %	1%	1%	0.99%	1%	1%	1%	1%	1%	1%
Net Income+	-11.09M	-12.86M	-20.55M	-26.05M	-32.76M	-33.94M	-29.15M	-29.07M	-47.91M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.16%	-0.6%	-0.27%	-0.26%	-0.04%	0.14%	0%	-0.65%
Net Income (Continuing)	-11.09M	-12.86M	-20.55M	-26.05M	-32.76M	-33.94M	-29.15M	-29.07M	-47.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.69	-1.43	-2.29	-1.46	-1.81	-1.49	-0.45	-0.29	-0.47
EPS Growth %	-	-1.07%	-0.6%	0.36%	-0.24%	0.18%	0.7%	0.36%	-0.62%
EPS (Basic)	-0.69	-1.43	-2.29	-1.46	-1.81	-1.49	-0.45	-0.29	-0.47
Diluted Shares Outstanding	16.14M	8.97M	8.97M	17.83M	18.06M	22.84M	64.54M	99.03M	101.04M
Basic Shares Outstanding	16.14M	8.97M	8.97M	17.83M	18.06M	22.84M	64.54M	99.03M	101.04M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.39M	22.16M	18.79M	59.55M	46.27M	37.96M	122.62M	87.55M	109.43M
Cash & Short-Term Investments	8.29M	22.02M	17.16M	57.31M	45M	36.83M	120.51M	82.97M	107.62M
Cash Only	8.29M	22.02M	17.16M	57.31M	45M	36.83M	12.59M	32.4M	34.1M
Short-Term Investments	0	0	0	0	0	0	107.92M	50.57M	73.53M
Accounts Receivable	19K	0	184K	558K	0	241K	0	0	532K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	63K	1.4M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	22.15K	-	-	-	-	-	-
Other Current Assets	0	49K	0	77K	265K	0	1.31M	955K	335K
Total Non-Current Assets+	17K	66K	1.7M	449K	862K	518K	399K	1.86M	1.47M
Property, Plant & Equipment	5K	14K	149K	430K	330K	184K	194K	1.56M	1.23M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	12K	52K	1.55M	19K	532K	334K	205K	297K	243K
Total Assets+	8.41M	22.23M	20.49M	60M	47.13M	38.48M	123.02M	89.4M	110.9M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	1.64%	-0.08%	1.93%	-0.21%	-0.18%	2.2%	-0.27%	0.24%
Total Current Liabilities+	20.39M	7.13M	2.68M	5.2M	5.55M	12.72M	13.4M	5.82M	10.51M
Accounts Payable	445K	537K	603K	1.6M	2.02M	2.85M	2.86M	1.81M	3.41M
Days Payables Outstanding	40.61K	-	9.57K	14.96K	15.66K	-	-	-	-
Short-Term Debt	16.99M	5.29M	0	0	0	5.83M	7M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.9M	0	0	776K	0	114K	0	1.61M	2.54M
Current Ratio	0.41x	3.11x	7.02x	11.45x	8.33x	2.98x	9.15x	15.03x	10.41x
Quick Ratio	0.41x	3.10x	6.50x	11.45x	8.33x	2.98x	9.15x	15.03x	10.41x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.43M	325K	506K	257K	14.29M	8.68M	2.16M	1.03M	747K
Long-Term Debt	5.12M	0	1.1M	0	13.95M	8.65M	2.15M	0	0
Capital Lease Obligations	0	0	46K	257K	144K	24K	2K	1.03M	747K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	310K	325K	460K	0	196K	0	3K	0	0
Total Liabilities	25.82M	7.45M	3.18M	5.46M	19.85M	21.4M	15.56M	6.86M	11.26M
Total Debt+	22.11M	5.29M	1.1M	356K	14.21M	14.63M	9.18M	1.34M	1.03M
Net Debt	13.82M	-16.73M	-16.07M	-56.96M	-30.79M	-22.2M	-3.41M	-31.06M	-33.06M
Debt / Equity	-	0.36x	0.06x	0.01x	0.52x	0.86x	0.09x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-2.46x	-105.79x	-	-71.25x	-27.02x	-38.34x	-86.76x	-12881.00x
Total Equity+	-17.41M	14.78M	17.31M	54.55M	27.28M	17.07M	107.46M	82.55M	99.64M
Equity Growth %	-	1.85%	0.17%	2.15%	-0.5%	-0.37%	5.29%	-0.23%	0.21%
Book Value per Share	-1.08	1.65	1.93	3.06	1.51	0.75	1.66	0.83	0.99
Total Shareholders' Equity	-17.41M	14.78M	17.31M	54.55M	27.28M	17.07M	107.46M	82.55M	99.64M
Common Stock	4K	4K	101K	18K	19K	29K	60K	68K	94K
Retained Earnings	-72.16M	-84.43M	-109.5M	-114.22M	-146.98M	-180.92M	-210.07M	-239.13M	-287.05M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-23K	-46K	0	0	0	-122K	-29K	61K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-11.19M	-7.97M	-18.29M	-23.09M	-29M	-28.95M	-28.18M	-31.71M	-38.26M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.29%	-1.29%	-0.26%	-0.26%	0%	0.03%	-0.13%	-0.21%
Net Income	-11.09M	-12.86M	-20.55M	-26.05M	-32.76M	-33.94M	-29.15M	-29.07M	-47.91M
Depreciation & Amortization	4K	4K	23K	39K	47K	50K	43K	123K	147K
Stock-Based Compensation	142	205K	496K	1.13M	2.42M	2.54M	2.33M	2.25M	3.59M
Deferred Taxes	0	1.35M	0	0	0	-82K	0	0	0
Other Non-Cash Items	2.45M	2.6M	2.3M	215K	236K	974K	-162K	-1.17M	-907K
Working Capital Changes	-1.49M	722K	-568K	1.58M	1.06M	1.51M	-1.23M	-3.85M	6.83M
Change in Receivables	49K	-30	-135K	-374K	293K	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	-1.11M	92K	66K	777K	417K	831K	9K	-1.05M	1.6M
Cash from Investing+	0	-13K	-158K	-9K	-32K	0	-107.37M	59.43M	-21.53M
Capital Expenditures	0	-13K	-158K	-9K	-32K	0	-159K	-137K	-35K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	829K	0	1.37M
Cash from Financing+	8.6M	21.72M	3.63K	73.21M	16.72M	20.77M	111.31M	-7.91M	61.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	52K	-520K	-1.85M	-415K	-340K	11.73M	-211K	464K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.19M	-7.99M	-18.45M	-23.1M	-29.03M	-28.95M	-28.33M	-31.85M	-38.29M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.29%	-1.31%	-0.25%	-0.26%	0%	0.02%	-0.12%	-0.2%
FCF per Share	-0.69	-0.89	-2.06	-1.30	-1.61	-1.27	-0.44	-0.32	-0.38
FCF Conversion (FCF/Net Income)	1.01x	0.62x	0.89x	0.89x	0.89x	0.85x	0.97x	1.09x	0.80x
Interest Paid	0	0	0	0	180K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-87.02%	-128.07%	-72.51%	-80.07%	-153.03%	-46.82%	-30.59%	-52.59%
Return on Invested Capital (ROIC)	-	-	-1115.19%	-	-	-	-45.35%	-32.72%	-65.46%
Debt / Equity	-	0.36x	0.06x	0.01x	0.52x	0.86x	0.09x	0.02x	0.01x
Interest Coverage	-	-2.46x	-105.79x	-	-71.25x	-27.02x	-38.34x	-86.76x	-12881.00x
FCF Conversion	1.01x	0.62x	0.89x	0.89x	0.89x	0.85x	0.97x	1.09x	0.80x

Frequently Asked Questions

Growth & Financials

Trevi Therapeutics, Inc. (TRVI) grew revenue by 0.0% over the past year. Growth has been modest.

Trevi Therapeutics, Inc. (TRVI) reported a net loss of $45.9M for fiscal year 2024.

Dividend & Returns

Trevi Therapeutics, Inc. (TRVI) has a return on equity (ROE) of -52.6%. Negative ROE indicates the company is unprofitable.

Trevi Therapeutics, Inc. (TRVI) had negative free cash flow of $44.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Trevi Therapeutics, Inc. (TRVI) 10-Year Financial Performance & Capital Metrics

TRVI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$51M -52.0%
Net Income -$48M -64.8%
EPS (Diluted) -0.47 -62.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -52.59% -71.9%
ROIC -65.46% -100.1%
Debt/Equity 0.01 -36.1%
Interest Coverage -12881.00 -14746.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 83 (top 17%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Expensive at 10.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.12%

ROCE

10Y Avg-126.56%

5Y Avg-59.84%

3Y Avg-45.11%

Latest-56.01%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	4K	0	23K	39K	47K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-4K	0	-23K	-39K	-47K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-0.7%	-0.21%	1%	-	-	-
Operating Expenses+	8.62M	8.24M	18.41M	26.64M	32.49M	32.48M	29.91M	33.92M	51.52M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.71M	2.14M	4.34M	7.31M	10.16M	9.49M	10.07M	10.24M	12.15M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	6.91M	6.09M	14.07M	19.34M	22.33M	22.98M	19.83M	23.68M	39.38M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	-24K	0	0	0	0	0	0	0
Operating Income+	-8.63M	-8.24M	-18.41M	-26.64M	-32.49M	-32.48M	-29.91M	-33.92M	-51.52M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.04%	-1.23%	-0.45%	-0.22%	0%	0.08%	-0.13%	-0.52%
EBITDA+	-8.62M	-8.23M	-18.39M	-26.61M	-32.44M	-32.43M	-29.86M	-33.8M	-51.38M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.05%	-1.23%	-0.45%	-0.22%	0%	0.08%	-0.13%	-0.52%
D&A (Non-Cash Add-back)	4K	4K	23K	39K	47K	50K	43K	123K	147K
EBIT	-8.63M	-8.24M	-20.5M	-26.64M	-32.32M	-32.76M	-28.02M	-28.71M	-47.94M
Net Interest Income+	0	-3.27M	-18K	792K	-278K	-1.19M	960K	4.36M	3.6M
Interest Income	2.61M	69K	156K	792K	178K	10K	1.74M	4.75M	3.6M
Interest Expense	0	3.34M	174K	0	456K	1.2M	780K	391K	4K
Other Income/Expense	-2.47M	-4.65M	-2.26M	577K	-287K	-1.49M	719K	4.83M	3.58M
Pretax Income+	-11.1M	-12.89M	-20.67M	-26.07M	-32.78M	-33.96M	-29.19M	-29.1M	-47.94M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	-8K	-26K	-124K	-18K	-18K	-21K	-36K	-32K	-30K
Effective Tax Rate %	1%	1%	0.99%	1%	1%	1%	1%	1%	1%
Net Income+	-11.09M	-12.86M	-20.55M	-26.05M	-32.76M	-33.94M	-29.15M	-29.07M	-47.91M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.16%	-0.6%	-0.27%	-0.26%	-0.04%	0.14%	0%	-0.65%
Net Income (Continuing)	-11.09M	-12.86M	-20.55M	-26.05M	-32.76M	-33.94M	-29.15M	-29.07M	-47.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.69	-1.43	-2.29	-1.46	-1.81	-1.49	-0.45	-0.29	-0.47
EPS Growth %	-	-1.07%	-0.6%	0.36%	-0.24%	0.18%	0.7%	0.36%	-0.62%
EPS (Basic)	-0.69	-1.43	-2.29	-1.46	-1.81	-1.49	-0.45	-0.29	-0.47
Diluted Shares Outstanding	16.14M	8.97M	8.97M	17.83M	18.06M	22.84M	64.54M	99.03M	101.04M
Basic Shares Outstanding	16.14M	8.97M	8.97M	17.83M	18.06M	22.84M	64.54M	99.03M	101.04M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.39M	22.16M	18.79M	59.55M	46.27M	37.96M	122.62M	87.55M	109.43M
Cash & Short-Term Investments	8.29M	22.02M	17.16M	57.31M	45M	36.83M	120.51M	82.97M	107.62M
Cash Only	8.29M	22.02M	17.16M	57.31M	45M	36.83M	12.59M	32.4M	34.1M
Short-Term Investments	0	0	0	0	0	0	107.92M	50.57M	73.53M
Accounts Receivable	19K	0	184K	558K	0	241K	0	0	532K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	63K	1.4M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	22.15K	-	-	-	-	-	-
Other Current Assets	0	49K	0	77K	265K	0	1.31M	955K	335K
Total Non-Current Assets+	17K	66K	1.7M	449K	862K	518K	399K	1.86M	1.47M
Property, Plant & Equipment	5K	14K	149K	430K	330K	184K	194K	1.56M	1.23M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	12K	52K	1.55M	19K	532K	334K	205K	297K	243K
Total Assets+	8.41M	22.23M	20.49M	60M	47.13M	38.48M	123.02M	89.4M	110.9M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	1.64%	-0.08%	1.93%	-0.21%	-0.18%	2.2%	-0.27%	0.24%
Total Current Liabilities+	20.39M	7.13M	2.68M	5.2M	5.55M	12.72M	13.4M	5.82M	10.51M
Accounts Payable	445K	537K	603K	1.6M	2.02M	2.85M	2.86M	1.81M	3.41M
Days Payables Outstanding	40.61K	-	9.57K	14.96K	15.66K	-	-	-	-
Short-Term Debt	16.99M	5.29M	0	0	0	5.83M	7M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.9M	0	0	776K	0	114K	0	1.61M	2.54M
Current Ratio	0.41x	3.11x	7.02x	11.45x	8.33x	2.98x	9.15x	15.03x	10.41x
Quick Ratio	0.41x	3.10x	6.50x	11.45x	8.33x	2.98x	9.15x	15.03x	10.41x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.43M	325K	506K	257K	14.29M	8.68M	2.16M	1.03M	747K
Long-Term Debt	5.12M	0	1.1M	0	13.95M	8.65M	2.15M	0	0
Capital Lease Obligations	0	0	46K	257K	144K	24K	2K	1.03M	747K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	310K	325K	460K	0	196K	0	3K	0	0
Total Liabilities	25.82M	7.45M	3.18M	5.46M	19.85M	21.4M	15.56M	6.86M	11.26M
Total Debt+	22.11M	5.29M	1.1M	356K	14.21M	14.63M	9.18M	1.34M	1.03M
Net Debt	13.82M	-16.73M	-16.07M	-56.96M	-30.79M	-22.2M	-3.41M	-31.06M	-33.06M
Debt / Equity	-	0.36x	0.06x	0.01x	0.52x	0.86x	0.09x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-2.46x	-105.79x	-	-71.25x	-27.02x	-38.34x	-86.76x	-12881.00x
Total Equity+	-17.41M	14.78M	17.31M	54.55M	27.28M	17.07M	107.46M	82.55M	99.64M
Equity Growth %	-	1.85%	0.17%	2.15%	-0.5%	-0.37%	5.29%	-0.23%	0.21%
Book Value per Share	-1.08	1.65	1.93	3.06	1.51	0.75	1.66	0.83	0.99
Total Shareholders' Equity	-17.41M	14.78M	17.31M	54.55M	27.28M	17.07M	107.46M	82.55M	99.64M
Common Stock	4K	4K	101K	18K	19K	29K	60K	68K	94K
Retained Earnings	-72.16M	-84.43M	-109.5M	-114.22M	-146.98M	-180.92M	-210.07M	-239.13M	-287.05M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-23K	-46K	0	0	0	-122K	-29K	61K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-11.19M	-7.97M	-18.29M	-23.09M	-29M	-28.95M	-28.18M	-31.71M	-38.26M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.29%	-1.29%	-0.26%	-0.26%	0%	0.03%	-0.13%	-0.21%
Net Income	-11.09M	-12.86M	-20.55M	-26.05M	-32.76M	-33.94M	-29.15M	-29.07M	-47.91M
Depreciation & Amortization	4K	4K	23K	39K	47K	50K	43K	123K	147K
Stock-Based Compensation	142	205K	496K	1.13M	2.42M	2.54M	2.33M	2.25M	3.59M
Deferred Taxes	0	1.35M	0	0	0	-82K	0	0	0
Other Non-Cash Items	2.45M	2.6M	2.3M	215K	236K	974K	-162K	-1.17M	-907K
Working Capital Changes	-1.49M	722K	-568K	1.58M	1.06M	1.51M	-1.23M	-3.85M	6.83M
Change in Receivables	49K	-30	-135K	-374K	293K	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	-1.11M	92K	66K	777K	417K	831K	9K	-1.05M	1.6M
Cash from Investing+	0	-13K	-158K	-9K	-32K	0	-107.37M	59.43M	-21.53M
Capital Expenditures	0	-13K	-158K	-9K	-32K	0	-159K	-137K	-35K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	829K	0	1.37M
Cash from Financing+	8.6M	21.72M	3.63K	73.21M	16.72M	20.77M	111.31M	-7.91M	61.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	52K	-520K	-1.85M	-415K	-340K	11.73M	-211K	464K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.19M	-7.99M	-18.45M	-23.1M	-29.03M	-28.95M	-28.33M	-31.85M	-38.29M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.29%	-1.31%	-0.25%	-0.26%	0%	0.02%	-0.12%	-0.2%
FCF per Share	-0.69	-0.89	-2.06	-1.30	-1.61	-1.27	-0.44	-0.32	-0.38
FCF Conversion (FCF/Net Income)	1.01x	0.62x	0.89x	0.89x	0.89x	0.85x	0.97x	1.09x	0.80x
Interest Paid	0	0	0	0	180K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-87.02%	-128.07%	-72.51%	-80.07%	-153.03%	-46.82%	-30.59%	-52.59%
Return on Invested Capital (ROIC)	-	-	-1115.19%	-	-	-	-45.35%	-32.72%	-65.46%
Debt / Equity	-	0.36x	0.06x	0.01x	0.52x	0.86x	0.09x	0.02x	0.01x
Interest Coverage	-	-2.46x	-105.79x	-	-71.25x	-27.02x	-38.34x	-86.76x	-12881.00x
FCF Conversion	1.01x	0.62x	0.89x	0.89x	0.89x	0.85x	0.97x	1.09x	0.80x

Frequently Asked Questions

Growth & Financials

Trevi Therapeutics, Inc. (TRVI) grew revenue by 0.0% over the past year. Growth has been modest.

Trevi Therapeutics, Inc. (TRVI) reported a net loss of $45.9M for fiscal year 2024.

Dividend & Returns

Trevi Therapeutics, Inc. (TRVI) has a return on equity (ROE) of -52.6%. Negative ROE indicates the company is unprofitable.

Trevi Therapeutics, Inc. (TRVI) had negative free cash flow of $44.0M in fiscal year 2024, likely due to heavy capital investments.